Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1995 1
2001 1
2009 4
2010 6
2011 3
2012 4
2013 1
2014 4
2015 3
2016 5
2018 1
2019 4
2020 4
2021 5
2022 1
2023 6
2024 4
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database.
Yan Q, Bruni C, Garaiman A, Mihai C, Jordan S, Becker MO, Elhai M, Dobrota R, Liubov P, Henes J, Hachulla E, Siegert E, Balbir-Gurman A, Cuomo G, Riemekasten G, Heitmann S, Beigi DMR, Ullman S, Sfikakis P, Ingegnoli F, Bernardino V, Truchetet ME, Vonk M, Galdo FD, Hoffmann-Vold AM, Shuang Y, Distler O; EUSTAR collaborators. Yan Q, et al. Among authors: becker mo. Ann Rheum Dis. 2025 Apr;84(4):620-631. doi: 10.1016/j.ard.2025.01.014. Epub 2025 Feb 1. Ann Rheum Dis. 2025. PMID: 39894689
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis.
Dobrota R, Garaiman A, Fligelstone K, Tyrrell Kennedy A, Roennow A, Allanore Y, Carreira PE, Czirják L, Denton C, Hesselstrand R, Sandqvist G, Kowal-Bielecka O, Bruni C, Matucci-Cerinic M, Mihai C, Gherghe AM, Mueller-Ladner U, Kvien T, Heiberg T, Distler O, Becker MO. Dobrota R, et al. Among authors: becker mo. RMD Open. 2024 Nov 27;10(4):e004653. doi: 10.1136/rmdopen-2024-004653. RMD Open. 2024. PMID: 39608865 Free PMC article.
Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort study.
Hoffmann-Vold AM, Petelytska L, Fretheim H, Aaløkken TM, Becker MO, Jenssen Bjørkekjær H, Brunborg C, Bruni C, Clarenbach C, Diep PP, Dobrota R, Durheim MT, Elhai M, Frauenfelder T, Huang S, Jordan S, Langballe E, Midtvedt Ø, Mihai C, Mulcaire-Jones E, Pugashetti JV, Sprecher M, Oldham J, Molberg Ø, Khanna D, Distler O. Hoffmann-Vold AM, et al. Among authors: becker mo. Lancet Rheumatol. 2025 Jul;7(7):e463-e471. doi: 10.1016/S2665-9913(25)00026-8. Epub 2025 May 14. Lancet Rheumatol. 2025. PMID: 40381640
A screening tool to detect interstitial lung disease in systemic sclerosis: the ILD-RISC Score.
Bruni C, Tofani L, Fretheim H, Liem SIE, Velauthapillai A, Bjørkekjær H, Barua I, Galetti I, Garaiman A, Becker MO, Hoffmann-Vold AM, de Vries-Bouwstra J, Vonk MC, Distler JHW, Matucci-Cerinic M, Distler O. Bruni C, et al. Among authors: becker mo. Rheumatology (Oxford). 2025 Aug 14:keaf445. doi: 10.1093/rheumatology/keaf445. Online ahead of print. Rheumatology (Oxford). 2025. PMID: 40811030
Intrapatient competition of VEXAS syndrome and CML clones.
Djerbi N, Zimmermann K, Roncador M, Becker MO, Manz MG, Balabanov S. Djerbi N, et al. Among authors: becker mo. Blood Adv. 2023 Nov 28;7(22):6815-6818. doi: 10.1182/bloodadvances.2023010814. Blood Adv. 2023. PMID: 37738165 Free PMC article. No abstract available.
59 results